Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity

J Med Chem. 2019 Aug 8;62(15):7042-7057. doi: 10.1021/acs.jmedchem.9b00516. Epub 2019 Jul 17.

Abstract

Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90. HDAC6 is involved in multiple disease-relevant pathways. Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand. We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degradation for the antiproliferation of multiple myeloma (MM). This new class of degraders exhibited improved potency and selectivity for the degradation of HDAC6. After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Cell Proliferation / drug effects
  • Cell Proliferation / physiology
  • Dose-Response Relationship, Drug
  • Drug Development / methods*
  • HeLa Cells
  • Hep G2 Cells
  • Histone Deacetylase 6 / antagonists & inhibitors*
  • Histone Deacetylase 6 / metabolism
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • MCF-7 Cells
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / enzymology*

Substances

  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • HDAC6 protein, human
  • Histone Deacetylase 6